TGEN - Targeted Genetics Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation

TGEN 8.230

+0.9%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael Bakunin who wrote (357)	4/17/2002 2:02:07 AM
From: Mike McFarland	of 557

I ran it through Pubmed--Papers which include IgG1b12 are mostly from the Aaron Diamond AIDS Research Center, Rockefeller University; the Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard; and the Department of Antiviral Research, Merck. Here is a googlie: google.com I did not find any US granted patents using IgG1b12, but I don't subscribe to Delphion, and I don't know what I am looking for yet, just IgG1 patents? I'm wont fill up the thread with all my silly google queries, but I will paste this: . Estimates of the total number of distinct antibody variable regions or antigen combining sites that an individual's B cells can theoretically produce range from 10 million upward. It is not surprising then that antibody responses to even simple antigens are generally very heterogeneous in terms of the numbers of different antibodies made, a bonus for the individual as far as immune protection goes but a hindrance to the immunologist trying to sort out and manipulate this intricate process whfreeman.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next